Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial

Chemotherapy for high-grade gliomas

“…In another approach, radiolabelled anti-EGF receptor antibodies have been injected into the tumour bed following resection of recurrent gliomas. The dosimetry and toxicity of this approach have been reported (Brady et al, 1992). Efficacy studies are ongoing.…”

Recent Achievements in the Development of Radiolabeled Monoclonal Antibodies for Diagnosis, Therapy and Biologic Characterization of Human Tumors

“…There was seen to be a clear relationship between dose of mAb administered and targeting of radiolabeled mAb to tumor, with all tumors >2cm in size being visualized at doses >40mg. MAb 425, an IgG,,, was developed by Koprowski's group at the Wistar Institute and is now extensively in use: labeled with iodine-125 and used in the treatment of glioblastorna multiform (49); and studied as an imaging agent, labeled with technetium-99m by Baum's group in Frankfurt. We are currently studying mAb 528, a murine IgG,, developed by Mendelsohn et al MAb RG 83852, a murine IgG,, developed by Schlessinger et al has also been used in a multicenter phase I trial in the United States.…”

Targeted radiotherapy of brain tumours

“…Brain-tumour-associated molecular targets that have been evaluated for radioimmunotherapy include the epidermal growth factor receptor (Brady et al, 1992) and the human neural cell adhesion molecule (NCAM), which is present both on glioma as well as normal neural tissue (Hopkins et al, 1998). However, the vast majority of targeted radiotherapy studies in brain tumour patients have utilised radiolabelled mAbs reactive with the tenascin molecule (Table 1).…”